Ranolazine in chronic total occlusion percutaneous coronary intervention

We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).PMID:38691399 | DOI:10.25270/jic/24.00059

Source: The Journal of Invasive Cardiology - May 1, 2024 Category: Cardiology Authors: Michaella Alexandrou Deniz Mutlu Athanasios Rempakos Ahmed Al Ogaili James W Choi Paul Poommipanit Khaldoon Alaswad Mir Babar Basir Rhian Davies Farouc A Jaffer Phil Dattilo Lorenzo Azzalini Nazif Aygul Niranjan Reddy Brian K Jefferson Sevket Gorgulu Jaik Source Type: research